Sat. Jan 16th, 2021

approval

The plan to temporarily place an observation wheel in Balboa Park’s Plaza de Panama has received the support of the city’s official park advisory group.



an aerial view of a city: A conceptual rendering of the proposed observation wheel shows the 148-foot attraction in Balboa Park's central Plaza de Panama. The for-charge ride promises unrivaled views of the city and is intended to reinvigorate the park. (Courtesy, City of San Diego)


© (Courtesy, City of San Diego)
A conceptual rendering of the proposed observation wheel shows the 148-foot attraction in Balboa Park’s central Plaza de Panama. The for-charge ride promises unrivaled views of the city and is intended to reinvigorate the park. (Courtesy, City of San Diego)

Thursday evening, the Balboa Park Committee voted 7-1 in favor of the short-term attraction, or what’s being called the Balboa Park Star, with one member abstaining. That means proponents — David and Leslie Cohn of the Cohn Restaurant Group and operator Sky Views of America — will aim to erect the part-time installation in the spring, following completion of additional steps and easing of state restrictions.

The vote marks an important first step in getting the controversial park ride

Read More ... Read More

ATLANTA, Nov. 19, 2020 /PRNewswire/ — Preferred Apartment Communities, Inc. (NYSE: APTS) (“PAC” or the “Company”) today announced that holders of the Company’s common stock voted to approve both Proposal 1, a proposal to approve an Articles of Amendment to give bylaw access to common stockholders, and Proposal 2, a proposal to approve an Articles of Amendment to reduce the Company’s call option on its Series A Redeemable Preferred Stock from 10 years to 5 years.  Of the 70.11% voting on Proposals 1 and 2, 97.75% and 95.4% voted in favor of Proposal 1 and Proposal 2, respectively.   

“We are extremely pleased that our common stockholders were overwhelmingly supportive of our efforts to enhance our corporate governance and improve our capital flexibility,” said Joel T. Murphy, the Company’s President and Chief Executive Officer. Mr. Murphy added, “Our Board of Directors is committed to best practices in corporate governance

Read More ... Read More

STOCKHOLM, Nov. 12, 2020 /PRNewswire/ — AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to initiate a clinical Phase I study with the drug candidate ACD856.

The Phase I study is AlzeCure’s second clinical study with ACD856, the lead drug candidate within the company’s NeuroRestore platform, which is developed as a symptom-relieving treatment for disease states where cognitive ability is impaired, such as in Alzheimer’s disease. The primary study obejective in the phase I study is to evaluate the drug candidate’s tolerability and safety.

“It is gratifying that just a few months after we completed our first clinical study with positive results, we now have all regulatory approvals in place

Read More ... Read More